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A B S T R A C T
Experimental work over the past several years has revealed an unexpected abundance of long natural antisense
transcripts (NATs) in eukaryotic species. In light of the proposed role of such RNA molecules in the regulation of
gene expression in the brain, attention is now focused on speciﬁc examples of neuronal NATs. Of particular
interest are NATs that are complementary to mRNAs encoding nitric oxide synthase (NOS), the enzyme re-
sponsible for production of the important gaseous neurotransmitter nitric oxide (NO). Here we study the tem-
poral expression proﬁle of murine Nos3as NAT in the brain. Notably, Nos3as NAT is known to act as a negative
regulator of Nos3 gene expression. The results of our quantitative analysis reveal diﬀerential expression of
Nos3as NAT during embryonic and post-embryonic stages of development of the brain. Also, they show that the
low levels of Nos3as NAT coincides with active neurogenesis. In addition we report on an inverse correlation
between the relative expression level of Nos3as NAT and the level of Nos3 protein. Thus our data raise the
hypothesis that the Nos3as NAT regulates neurogenesis through suppression of Nos3 gene activity. This idea is
further supported by experiments conducted on the olfactory bulbs and cultured neuroblastoma cells.
1. Introduction
Long natural antisense transcripts (NATs) are endogenous RNA
molecules that are complementary to RNA transcripts of already es-
tablished function. They are longer than 200 nt and depending on their
origin can be classiﬁed as cis-encoded and trans-encoded NATs. Cis-
encoded NATs are produced from the same loci as their sense coun-
terparts whereas trans-encoded NATs are transcribed from diﬀerent
loci. Recently, the cumulative eﬀorts of molecular biologists and
bioinformaticians have led to the discovery of many long NATs in eu-
karyotic systems [1,2]. Probably the most exciting outcome of these
studies is that long NATs appear to be especially prevalent in the ner-
vous system [3]. One important class of long NATs that has been stu-
died in both vertebrates and invertebrates contains RNA molecules in-
volved in regulating the production of the endogenous gaseous
neurotransmitter nitric oxide (NO) [4–7]. In mammals, NO has been
implicated in many physiological processes including the regulation of
blood ﬂow, neurotransmission, platelet aggregation and the immune
response [8–10]. It is produced by three major nitric oxide synthase
(NOS) isoforms: neuronal NOS (NOS1), inducible NOS (NOS2) and
endothelial NOS (NOS3). In the brain, these isoforms are expressed
either constitutively (NOS 1 and NOS3) or inducibly (NOS2). Notably,
long NATs complementary to mRNAs encoding all three mammalian
NOS isoforms have been reported in recent literature [5,6,11,12]. Ro-
dent Mm-antiNos1 and Nos3as RNAs belong to a class of cis-encoded
NATs and function as negative regulators of the Nos1 and Nos3 genes
respectively [12,13]. Anti-NOS2a is an example of a trans-encoded NAT
and is likely to be involved in the regulation of NOS2 gene in humans
[6]. However, while Mm-antiNos1, Nos3as and anti-NOS2a NATs were
found to be present in the nervous system, the temporal expression
proﬁle in the brain has been reported only for the Mm-antiNos1 RNA
[12]. In this study we report on the results of a quantitative RNA
analysis that reveals diﬀerential expression of Nos3as RNA during em-
bryonic and post-embryonic stages of brain development. We demon-
strate an inverse correlation between the relative expression level of
Nos3as RNA and the level of Nos3 protein produced in the brain. We
also show that in the olfactory bulb (OB) Nos3as RNA expression re-
mains very low in both embryonic and perinatal mice. In addition, we
report that neuronal diﬀerentiation of murine neuroblastoma Neuro2a
cells is associated with up-regulation of Nos3as RNA. Taken together
our data suggest that Nos3as RNA can be involved in the regulation of
neurogenesis.
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2. Methods
2.1. Animal use and tissue collection
Mice (CD1) and mouse embryos were killed by decapitation or
cervical dislocation in accordance with Home Oﬃce guidelines and
either the whole brain or the olfactory bulb were rapidly dissected in
ice cold PBS and frozen in liquid nitrogen to minimise RNA degrada-
tion. All procedures were performed with the approval of the University
of Sussex Animal Welfare and Ethical Review Committee and in ac-
cordance with UK Home Oﬃce regulations.
2.2. Maintenance and diﬀerentiation of Neuro2a cells
Mouse Neuro2a cells were obtained from the American Type
Culture Collection. Cells were cultured in DMEM (Gibco) containing
10% heat-inactivated FCS (PAN Biotech) and penicillin/streptomycin
(Gibco) at 37 °C in 95% air, 5% CO2. For diﬀerentiation assays,
Neuro2a cells were plated into 100 mm Petri dishes to reach 25%
conﬂuence. The cells were then diﬀerentiated by incubation in DMEM
containing reduced serum medium (0.1% FCS) and 30 μM retinoic acid
(Sigma). After 4 days the cells were washed with PBS and collected for
further analysis.
2.3. Real-time reverse transcription-PCR
Total RNAs were extracted from individual samples of brain tissue
(n = at least 4 animals per group) or Neuro2a cultured cells by means
of the Absolutely RNA Microprep or Miniprep kits (Agilent
Technologies). To remove all traces of genomic DNA the extracted
RNAs were treated with DNase TURBO (Ambion). Puriﬁed RNAs were
copied into cDNAs using the iScript cDNA synthesis kit (Bio-Rad).
cDNAs were ampliﬁed and analyzed on a Mx3000P real-time cycler
(Stratagene) using the iTaq Universal SYBR Green Supermix (Bio-Rad).
We used primers 5′- AGAGAATTCTGGCAACAGAG-3 and 5′-
TGGGTGCGCAATGTGAGT-3′ for detection of Nos3 mRNA, primers 5′-
GCCTCCACGCTATTTACC-3′ and 5′- TCCTCATCAGGTGAGCCT-3' for
detection of Nos3as RNA and primers 5′-TGTCTCCTGCGACTTCAAC-3′
and 5′-AGCCGTATTCATTGTCATACC-3′ for detection of GAPDHmRNA.
The identity of all PCR products was conﬁrmed by sequencing. The
amount of target transcript, normalized to an endogenous reference
(GAPDH) and relative to a calibrator was calculated as 2−ΔΔCt where
ΔΔCT = ΔCT − ΔCT(CAL). ΔCT and ΔCT(CAL) are the diﬀerences in
threshold cycles for target and reference (GAPDH) measured in the
samples and in the calibrator (CAL) respectively. The ratio between
Nos3as RNA and Nos3 mRNA expression was calculated as
2−ΔCt(Nos3as)/2−ΔCt(Nos3). The results of real-time RT-PCR were statis-
tically evaluated by one-way ANOVA with post-hoc Tukey HSD test.
2.4. Western blotting
Brains were homogenized on ice in seven volumes of RIPA lysis
buﬀer (Source BioScience) supplemented with phosphatase and pro-
tease inhibitor cocktails (Sigma-Aldrich). The homogenates were in-
cubated for 1 h on ice and insoluble constituents were removed by
centrifugation of the homogenates at 16,000 g and 4° C for 30 min.
Supernatants were collected and protein quantiﬁcation was performed
using the Quick Start Bradford protein assay (Bio-Rad). Equal amounts
of proteins were loaded on a TruPAGE 4–12% polyacrylamide gradient
gel (Sigma-Aldrich) and run at slow voltage. Separated proteins were
blotted onto Amersham Hybond-P PVDF membrane (GE Healthcare Life
Sciences) using the Mini Trans-Blot electrophoretic transfer module
(Bio-Rad). After protein transfer, the membrane was cut into two sec-
tions. The upper section contained proteins with a molecular weight
greater than 50 kDa and the lower section contained proteins with a
molecular weight below 50 kDa. Both sections were blocked with 5%
non-fat dry milk in Tris-buﬀered saline (TBS) containing 0.15% Tween-
20. The upper section was then incubated with rabbit polyclonal anti-
Nos3 Ab-1177 antibodies (Sigma-Aldrich) at 1:500 and the lower sec-
tion was incubated with rabbit polyclonal anti-GAPDH ABS16 anti-
bodies (Millipore) at 0.25 μg/ml. HRP-conjugated goat anti-rabbit IgG
at 1:2000 (Millipore) was used to detect the bound primary antibodies.
Immunoreactive protein bands were detected and visualized using the
Immobilon western chemiluminescent HRP substrate (Millipore).
3. Results
3.1. Quantitative RNA analysis reveals diﬀerential expression of Nos3as
RNA during embryonic and post-embryonic stages of brain development
Previous studies have shown that NO produced by Nos3 plays an
important role in the regulation of neural precursor cell proliferation
[14,15]. Since Nos3as acts as a negative regulator of Nos3 gene ex-
pression [5] it would be worthwhile to investigate if this NAT is also
involved in neurogenesis. Consequently, we conducted a quantitative
real-time RT-PCR analysis of Nos3as RNA and Nos3mRNA expression at
diﬀerent stages of mouse brain development including embryonic day
(E) 9.5, E11.5, E15.5 and E18.5, postnatal day (P) 1 and P20, and 4-
month-old adults. Our data show that Nos3 mRNA expression under-
goes a slow modest increase during embryogenesis but gradually de-
creases during the postnatal period (Fig. 1A). The temporal expression
proﬁle of the Nos3as RNA exhibits a noticeable diﬀerence. Nos3as RNA
is present at a just detectable level in early embryonic brain but there is
then a notable increase in its expression at E15.5. The Nos3as expres-
sion reaches its peak in newborn mice and rapidly decreases by P20
remaining quite stable until at least 4 months (Fig. 1B). These ﬁndings
demonstrate that Nos3as RNA expression is diﬀerentially regulated
during embryonic developments and in adults. Also, they indicate that
the low level of Nos3as RNA coincides with phases of extensive neu-
rogenesis in the embryo.
Another interesting observation is obtained when we determine the
ratio between Nos3as RNA and Nos3 mRNA expression (Fig. 1C). The
calculations show that in the early embryonic stages (E9.5 and E11.5)
the level of Nos3as RNA in the brain is very low compared to Nos3
mRNA (approximately 1:20). This suggests that the reported suppres-
sive eﬀect of Nos3as RNA on the Nos3-NO pathway [5,13] will be either
very weak, or even negligible during these stages of development.
However, at E15.5 the Nos3as RNA/Nos3 mRNA ratio begins to grow
and is further increased at E18.5 to approximately 1:3. The ratio re-
mains relatively stable at later stages permitting an increase in the
suppressive eﬀect of Nos3as NAT on the Nos3 expression.
3.2. Immunoblotting analysis shows an inverse correlation between the
expression of Nos3as RNA and the level of Nos3 protein
Our ﬁndings that Nos3as RNA is diﬀerentially expressed during
embryonic and post-embryonic stages of brain development raised the
possibility that this NAT could play a role in neurogenesis through the
regulation of Nos3 gene expression. To provide support for this hy-
pothesis we investigated whether the observed changes in the relative
expression level of Nos3as RNA are accompanied by alterations in Nos3
protein production. Speciﬁcally, we studied Nos3 protein expression in
the embryonic (E15.5), early postnatal (P5) and adult (5 months) brain.
The Western blot results demonstrate that Nos3 protein is present at a
relatively high level at E15.5 but it is down-regulated at P5 and even
further down-regulated in 5-month-old animals (Fig. 2A). Given similar
levels of Nos3 mRNAs in E15.5 embryos and in the early postnatal
animals, these observations are indicative of post-transcriptional reg-
ulation of Nos3 gene expression. In parallel experiments, we used brain
tissue samples from the same animals for quantitative RNA analysis. As
expected, we found that the Nos3as RNA/Nos3 mRNA ratio is gradually
increased over time after E15.5 (Fig. 2B). Thus, these observations
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reveal an inverse correlation between the relative expression of Nos3as
RNA and the level of Nos3 protein produced in the brain.
3.3. Quantitative analysis of Nos3 mRNA and Nos3as RNA expression in
the olfactory bulb
It is known that neurogenesis in mammals mainly occurs during the
embryonic development, but also in restricted regions of the adult
brain. To examine if the observed association between active neuro-
genesis and down-regulation of Nos3as RNA is of importance, we per-
formed quantitative RT-PCRs on RNA extracted from the olfactory bulb
(OB). Notably, OB is a neural structure of the mammalian forebrain
involved in adult neurogenesis. OBs dissected from the embryonic
(E15.5 and E18.5), postnatal (P24), and adult (5 months) brain were
used in this experiment. We found that the expression proﬁle of Nos3
mRNA in the OBs was generally similar to that observed at the level of
the whole brain (Fig. 3A). The expression proﬁle of Nos3as RNA,
however, exhibited some recognisable diﬀerences. Firstly, Nos3as RNA
is present at a very low level at E15.5, E18.5, and even at P24 (Fig. 3B).
Secondly, the expression level of Nos3as RNA compared to that of Nos3
mRNA remains very low up until P24 (Fig. 3C). Even in 5-month-old
OBs this ratio is lower than those calculated for whole brains at E18.5,
P1, P20 and 4 months. Taken together these ﬁndings suggest that the
suppressive eﬀect of Nos3as RNA on Nos3 gene expression could be
substantially delayed in the OB.
3.4. Nos3 mRNA and Nos3as RNA exhibit concurrent reciprocal changes in
their expression during neuronal diﬀerentiation of Neuro2a cells
Characteristic changes in the expression of Nos3as RNA during
embryonic and post-embryonic stages of development of the brain and
the OBs suggest a possible role of this NAT in the regulation of neu-
rogenesis. To provide additional support for this hypothesis we chose
the Neuro2a cell line, which is a well-established model system for
studying the process of neuronal diﬀerentiation. We successfully in-
duced the cells to diﬀerentiate into neurons by employing a combina-
tion of retinoic acid and reduced serum levels in the culture medium
(Fig. 4A and B) and used them in our quantitative RT-PCR analysis.
Interestingly, these experiments reveal concurrent reciprocal changes in
the expression of the Nos3as RNA and Nos3 mRNA in undiﬀerentiated
and diﬀerentiated Neuro2a cells. Speciﬁcally, the expression of the
Fig. 1. The expression proﬁles of Nos3 mRNA and Nos3as RNA in the brain during em-
bryonic development and postnatal life. (A) Quantitative RT-PCR analysis of Nos3 mRNA
expression. One-way ANOVA with post-hoc Tukey HSD test reveals that there is a sta-
tistically signiﬁcant diﬀerence between 1 and 3 (p< 0.01), 1 and 4 (p< 0.01), 1 and 5
(p< 0.01), 2 and 4 (p< 0.01), 3 and 4 (p< 0.01), 4 and 6 (p< 0.01), 4 and 7
(p< 0.01), 5 and 7 (p< 0.05). There is no statistically signiﬁcant diﬀerence between
other pairs. (B) Quantitative RT-PCR analysis of Nos3as RNA expression. One-way
ANOVA with post-hoc Tukey HSD test reveals that there is a statistically signiﬁcant dif-
ference between 1 and 4 (p<0.01), 1 and 5 (p< 0.01), 1 and 6 (p<0.05), 1 and 7
(p< 0.05), 2 and 4 (p< 0.01), 2 and 5 (p< 0.01), 2 and 6 (p< 0.05), 2 and 7
(p< 0.05), 3 and 4 (p< 0.01), 3 and 5 (p< 0.01), 4 and 6 (p< 0.05), 4 and 7
(p< 0.05), 5 and 6 (p<0.01), 5 and 7 (p<0.01). There is no statistically signiﬁcant
diﬀerence between other pairs. Real-time RT-PCR experiments were performed on in-
dividual brains dissected at diﬀerent stages of embryonic development (white bars) and
postnatal life (grey bars). (C) The ratio between Nos3as RNA and Nos3 mRNA expression.
The ratios were calculated as 2-ΔCt(Nos3as)/2-ΔCt(Nos3).
1 - E9.5, 2 - E11.5, 3 - E15.5, 4 - E18.5, 5 - P1, 6 - P20, 7 - 4 months.
Fig. 2. Inverse correlation between Nos3 protein production and relative expression level
of Nos3as RNA. (A) A representative immunoblot showing the level of Nos3 protein in the
mouse brain. Brain tissue lysates prepared from E15.5 (1), P5 (2) and 5 month old (3)
mice were subjected to Western blot analysis with either anti-Nos3 (the upper section) or
anti-GAPDH (the lower section) antibodies. (B) The 100% stacked column chart shows
the relative percentage of Nos3as RNA (light grey) and Nos3mRNA (dark grey) expression
levels in brain tissues dissected from E15.5 (1), P5 (2) and 5 month old (3) animals.
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Nos3 mRNA was higher in the undiﬀerentiated cells than in the dif-
ferentiated neurons (Fig. 4C), whereas the expression of Nos3as RNA
exhibited the opposite dynamics, namely it was upregulated in diﬀer-
entiated neurons relative to the undiﬀerentiated cells (Fig. 4D). These
data indicate that Nos3as RNA could be involved in the regulation of
neuronal diﬀerentiation of neuroblastoma cells through down-reg-
ulating the Nos3-NO pathway.
4. Discussion
Experimental work over the past several years has revealed an im-
portant role of NO generated by NOS enzymes in the regulation of
neurogenesis. The common view among neuroscientists is that NO
modulates the balance between proliferation and diﬀerentiation of
neural stem cells in a concentration- and source-dependent manner
[16,17]. For example, it was demonstrated that NO produced by Nos3
stimulates proliferation of neural precursor cells [15,18]. This ﬁnding
was rather unexpected because Nos3 is traditionally believed to be
primarily responsible for the production of NO within the cardiovas-
cular system [19]. However, recent studies show that Nos3 plays an
important role in physiological and pathophysiological processes in the
brain such as synaptic plasticity, neuroprotection and neurogenesis
[15,18,20,21]. Notably, it is expressed in various brain cell types, in-
cluding endothelial cells, astrocytes and several neuronal types
[22–24].
Given the diversity of neural functions mediated by Nos3 and the
well-known neurotoxic properties of excessive levels of NO [for a re-
view, see 8], it is not surprising that Nos3 expression in the brain is
tightly controlled. This is achieved through a variety of regulatory
mechanisms operating at diﬀerent levels [25,26]. An additional im-
portant point emerges from recent studies showing that the expression
of the Nos3-encoding gene in rodents and in humans is negatively
controlled by Nos3as RNA [5,13]. Nos3as RNA is a long cis-encoded
NAT, which is also known as sONE or autophagy 9-like 2 RNA [27].
Because Nos3 was shown to be involved in the regulation of neural stem
cell proliferation one may propose that Nos3as RNA is also an important
part of the mechanisms regulating neurogenesis in mammals. However,
while Nos3as RNAs was previously shown to be expressed in the brain,
the question of its potential neuronal function has not been addressed
yet.
Here we report the temporal expression proﬁles of Nos3as RNA and
Nos3 mRNA in the embryonic and adult brain. We found that the
Nos3as RNA/Nos3 mRNA ratio is very low in the early embryo but in-
creases noticeably at later stages of embryogenesis and then remains
quite high in the brain of adults. Since Nos3as RNA acts as a negative
regulator of Nos3 gene expression these data suggested that from E18.5
onwards the level of NO produced by Nos3 in the brain will be gra-
dually decreased with age. Importantly, this proposition is supported by
the results of our Western blot experiments, which revealed an inverse
correlation between the relative expression level of Nos3as RNA and the
level of Nos3 protein in the brain. Thus, considering the known pro-
liferative role of Nos3-derived NO, these ﬁndings correlate well with
published observations of high rate of proliferation of neural stem cells
in the embryo and low rate of proliferation in the adult brain [for a
review, see [28]]. Therefore, we can hypothesise that Nos3as RNA is
Fig. 3. The expression proﬁles of Nos3 mRNA and Nos3as RNA in the OBs during em-
bryonic development and postnatal life. (A) Quantitative RT-PCR analysis of Nos3 mRNA
expression. One-way ANOVA with post-hoc Tukey HSD test reveals that there is a sta-
tistically signiﬁcant diﬀerence between 1 and 3 (p< 0.01), 1 and 4 (p< 0.01), 2 and 3
(p< 0.01), 2 and 4 (p< 0.01). There is no statistically signiﬁcant diﬀerence between
other pairs. (B) Quantitative RT-PCR analysis of Nos3as RNA expression. One-way
ANOVA with post-hoc Tukey HSD test reveals that there is a statistically signiﬁcant dif-
ference between 1 and 4 (p< 0.05), 2 and 4 (p<0.01), 3 and 4 (p< 0.01). There is no
statistically signiﬁcant diﬀerence between other pairs. Real-time RT-PCR experiments
were performed on OBs dissected from embryonic (white bars) and adult (grey bars)
brain. (C) The ratio between Nos3as RNA and Nos3 mRNA expression. The ratios were
calculated as 2-ΔCt(Nos3as)/2-ΔCt(Nos3).
1 – E15.5, 2 - E18.5, 3 – P24, 4 - 5 months.
Fig. 4. Quantitative analysis of Nos3 mRNA and Nos3as RNA expression during neuronal
diﬀerentiation of Neuro2a cells. (A) Undiﬀerentiated Neuro2a cells. (B) Neuro2a cells
diﬀerentiated into neurons. (C) Quantitative real-time RT-PCR analysis of Nos3 mRNA
expression. (D) Quantitative real-time RT-PCR analysis of Nos3as RNA expression. U –
undiﬀerentiated Neuro2a cells, D – diﬀerentiated Neuro2a cells. The values represent the
average of three independent experiments.
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involved in neurogenesis through the regulation of Nos3 gene expres-
sion.
To provide additional support for our hypothesis we performed
quantitative analysis of Nos3as RNA in the OBs. Our main reason for
choosing OBs was that these structures of the brain are known to be
active sites of the late stages of adult neurogenesis. Interestingly, our
experiments have shown that the Nos3as RNA/Nos3 mRNA ratio in the
OBs remained very low in both embryonic and perinatal mice. This is in
direct contrast to that observed at the whole-brain level. Consequently,
we can speculate that the suppressive eﬀect of Nos3as RNA on Nos3
gene expression will be substantially delayed in the OBs allowing adult
neurogenesis to occur.
Another interesting aspect of this study arises from the results of our
experiments conducted on cultured marine Neuro2a cells. This cell line
possesses the ability to diﬀerentiate into neurons in response to serum
deprivation [29,30]. Notably, Neuro2a cells have been successfully
utilised to investigate the role of NO in neuronal diﬀerentiation [31].
Using this model system, we discovered that Nos3as RNA and Nos3
mRNA exhibit concurrent reciprocal changes in their expression in
undiﬀerentiated and diﬀerentiated cells. Furthermore, we found that
diﬀerentiation of Neuro2a cells in neurons is associated with up-reg-
ulation of Nos3as RNA. Thus, these in vitro observations indicate that
the Nos3as RNA could be involved in the control of neuronal diﬀer-
entiation.
In the light of the data reported here we can suggest that the Nos3as
RNA may play a role in neurogenesis through the regulation of the
Nos3-NO pathway. Our ﬁndings, however, do not rule out other me-
chanisms by which this NAT can execute its function in the brain.
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